P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans

International Journal of Gynecological Cancer

Volumn 13, Issue 4, 2003, Pages 444-449

  Pegoraro, R J ^a   Moodley, M ^b   Rom, L ^a   Chetty, R ^a   Moodley, J ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Black South Africans; BRCA 1 and 2; Ovarian cancer; p53 codon 72

Indexed keywords

ARGININE; BRCA2 PROTEIN; DNA; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; BLOOD; CANCER RISK; CANCER TISSUE; CARCINOGENESIS; CAUCASIAN; CODON; CONTROLLED STUDY; CYSTADENOCARCINOMA; EPITHELIAL OVARIAN CANCER; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; NEGRO; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; SOUTH AFRICA; TUMOR SUPPRESSOR GENE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA; DNA, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 1242339580     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13333.x     Document Type: Article

References (35)

1. Parker SL, Tong T, Bolden S et al. Cancer statistics. CA Cancer J Clin 1997;47:5-27.
2. Benjamin I, Rubin SC. Modern treatment options in epithelial ovarian carcinoma. Curr Opin Obstet Gynecol, 1994;10:29-32.
3. Sitas F. Histologically diagnosed cancers in South Africa. S Afr Med J 1988;84:344-8.
4. Nunns D, Symonds P, Ireland D. Surgical management of advance ovarian cancer. Obstet Gynecol Surv 2000;55:746-51.
5. Lynch HT, Casey MJ, Lynch J et al. Genetics and ovarian carcinoma. Semin Oncol 1998;25:265-80.
6. Aunoble B, Sandes R, Didier E et al. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000;16:567-76.
7. Kohler MF, Marks JR, Weiseman RW et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-9.
8. Milner BJ, Allan LA, Eccles DM et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993;53:2128-32.
9. Angelopoulou K, Levesque MA, Katsaros D et al. Exon 5 of the p53 gene is a target for deletions in ovarian cancer. Clin Chem 1998;44:72-7.
10. Geisler JP, Geisler HE, Miller GA et al. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 2000;77:278-82.
11. Pieretti M, Hopenpayn-Rich C, Khattar NH et al. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20:11-23.
12. Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 1999;6:193-7.
13. Steinmann D, Bremer M, Rades D et al. Mutations of the BRCA1 and 2 genes in patients with bilateral breast cancer. Br J Cancer 2001;85:850-8.
14. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705-13.
15. Gao O, Tomlinson G, Das S et al. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 2001;109:239-40.
16. Barnholtz-Sloan JS, Tainsky MA, Abrams J et al. Ethnic differences in survival among women with ovarian carcinoma. Cancer 2002;94:1886-93.
17. Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993;71:1534-40.
18. Chetty R, Pulford K, Jones M et al. SCL/Tal-1 expression in T-acute lymphoblastic leukaemia: an immunohistochemical and genotypic study. Hum Pathol 1995;26:994-8.
19. Pegoraro RJ, Moodley J, Naiker S et al. The p53 codon 72 polymorphism in black South African women and the risk of cervical cancer. Br J Obstet Gynaecol 2000;107:164-5.
20. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA 1 and BRCA 2 among Ashkenazi Jews. New Engl J Med 1997;336:1401-8.
21. Frank TS, Deffenburgh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10000 individuals. J Clin Oncol 2002;20:1480-90.
22. Panguluri RC, Brody LC, Modali R et al. BRCA1 mutations in African Americans. Hum Genet 1999;105:28-31.
23. Ioannidis JP, Trikalinos TA, Ntzani EE et al. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361:567-71.
24. Suzuki M, Saito S, Saga Y et al. Loss of heterozygosity on chromosome 6p27 and p53 mutations in epithelial ovarian cancer. Med Oncol 1998;15:119-23.
25. Diebold J. Molecular genetics of ovarian carcinomas. Histol Histopathol 1999;14:269-77.
26. Buller RE, Sood A, Fullenkamp C et al. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis prognosis. Cancer Gene 1997;4:239-45.
27. Papadakis EN, Dokianakis DN, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of the breast cancer. Mol Cell Biol Res Commun 2000;3:389-92.
28. Pegoraro RJ, Rom L., Lanning, PA et al. p53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. Int J Gynecol Cancer 2002;12:383-8.
29. Beckman G, Birgander R, Sjalander A et al. In p52 polymorphism maintained by natural selection. Hum Hered 1994;44:266-70.
30. Ness RB, Grisso JA, Klapper J et al. Racial differences in ovarian cancer risk. J Natl Med Assoc 2000;92:176-82.
31. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci 1996;93:15335-40.
32. Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 1997;15:887-8.
33. Zhu J, Jiang J, Zhou W et al. Differential regulation of cellular targets genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 1999;18:2149-55.
34. Marin MC, Jost CA, Brooks LA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nature Genet 2000;25:47-54.
35. Kersemaekers AM, Hermans J, Fleuren GJ, van de Vijvers MJ. Loss of heterozygosity for defined regions on chromosomes 3, 11, and in carcinoma of the uterine cervix. Br J Cancer 1998;77:192-200.